[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"barretts-esophagus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:barretts-esophagus":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,68,97,125,149,170,193,221,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100618732","enhancing-screening-practices-for-be-100618732",false,"NCT07335445","Enhancing Screening Practices for BE","Enhancing Screening Practices for Barrett's Esophagus","Inclusion Criteria:\n\n* 18 years of age or older\n* Have a scheduled appointment with a participating provider\n\nExclusion Criteria:\n\n* Less than 18 years of age","ALL","18 Years",{"count":19,"type":20},3000,"ESTIMATED","INTERVENTIONAL",[23],"NA","Previous studies have shown that screening for Barrett's esophagus (BE), the main risk factor for esophageal adenocarcinoma, is under-utilized in the primary care setting. In fact less than 35% of eligible patients are screened despite endorsement for screening by the major GI societies in patients with risk factors. The purpose of this study is to examine current screening practices and determine if implementation of screening reminders can optimize screening practices for Barrett's Esophagus within a large, academic based healthcare system in NJ.",[26],"Barrett's Esophagus",[28,29,30],"screening","barrett's esophagus","barrett's","NOT_YET_RECRUITING","2026-05-03",{"date":34,"type":35},"2026-05-05","ACTUAL",{"date":37,"type":20},"2026-05",{"date":39,"type":20},"2029-06",{"name":41,"class":42},"Rutgers, The State University of New Jersey","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100573640","navicam-for-detection-of-barretts-esophagus-100573640","NCT06748911","Navicam for Detection of Barrett's Esophagus","Use of a Detachable String Capsule for Evaluation of Barrett's Esophagus","DS-MCE-BE","Inclusion Criteria\n\n* Adults greater than or equal to 22 years of age with or without Barrett's Esophagus\n* All Patients:\n\n  o Have had an endoscopy within 1 year of baseline enrollment\n* Patients with Barrett's Esophagus:\n\n  * Presence of at least 1cm of salmon colored mucosa with corresponding biopsies showing intestinal metaplasia who are treatment naïve and undergoing surveillance Or\n  * Chronic Gastro Esophageal Reflux Disease (GERD) patients with at least 3 additional risk factors that meet Barrett's Esophagus screening criteria per latest clinical guidelines\n\nExclusion Criteria\n\n* Inability to comprehend or read the consent form\n* Have an oropharynx, esophageal, or gastro-esophageal tumor\n* Ongoing symptoms of dysphagia\n* Presence of active clinically significant stricture\n* History of stricture requiring dilation\n* Presence of pacemaker or implanted cardiac defibrillator\n* History of esophageal surgery with the exception of fundoplication\n* Pregnancy\n* History of surgery or obstructive process of the small bowel\n* BMI \\> 38","22 Years",{"count":54,"type":20},57,[23],"Using a non-invasive capsule system to achieve optimal viewing angles of the esophagus for detection of Barrett's esophagus",[26],"RECRUITING","2026-03-30",{"date":61,"type":35},"2026-04-03",{"date":63,"type":35},"2025-02-20",{"date":65,"type":20},"2026-06-30",{"name":67,"class":42},"Mayo Clinic",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100556305","a-study-of-barretts-esophagus-patients-to-investigate-quality-of-life-and-fear-of-cancer-and-optimize-a-risk-model-based-on-biomarkers-and-new-technologies-to-better-predict-the-development-of-cancer-100556305","NCT06523374","A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer","Endoscopic Brush Cytology and Single Cell Clonal Dynamics of Early Esophageal Adenocarcinoma for Defining Cost Effective Surveillance Strategies and Prediction of Cancer Recurrence: Prospective Pilot Cohort Study in Preparation of a Randomized Controlled Trial to Determine the Feasibility of a Risk Stratification Model for Barrett Esophagus Patients Based on Brush Cytology, and to Test Novel High Throughput Methods for Assessing Biomarkers for Future Use","Endeavor-1","Inclusion Criteria:\n\n* Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of early esophageal Barrett cancer\n* Capable of receiving informed consent and of giving permission\n* Age 18 and upward\n\nExclusion Criteria:\n\n* Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion\n* Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)\n* Esophageal varices\n* Uncontrollable coagulation disorders\n* Undergoing chemotherapy or immunotherapy or received chemotherapy \\\u003C 6 weeks prior to endoscopy\n* Undergoing radiotherapy within the esophageal region or received chemotherapy \\\u003C 6 months prior to endoscopy\n* WHO score \\> 3",{"count":77,"type":20},50,[23],"This study serves, in part, to prepare for a future large cohort study. The goal of the study is:\n\n1. The collection of various tissue samples (blood, biopsies and \"esophageal brushes\") and their analysis.\n2. To set up standardized methods for different genetic analyses (DNA-FISH and so-called single cell sequencing) on the esophageal tissue samples.\n3. Evaluating the quality of life of Barrett's Esophagus patients and the degree of fear of getting cancer.\n\nPatients with a Barrett's Esophagus can participate in the study if they are minimally 18 years old, are capable of giving informed consent (fully understanding what the study entails before giving consent to participate), have Barrett Esophagus and are referred to one of the participating centers due to suspicion of high-grade dysplasia or early esophageal cancer, for which the participant will be evaluated by endoscopic imaging and biopsy.\n\nStudy procedures:\n\n* An intake consultation will be planned, wherein the eligibility criteria will be assessed, and participant characteristics will be collected.\n* A routine gastroscopy will be planned twice during which several minimally-invasive interventions will be performed: drawing a blood sample, brush cytology during the endoscopy (a brush is used to obtain cells from the surface of the esophagus) and obtaining biopsy samples (small pieces of tissue). Each participant will need to undergo all the interventions.\n* Patients will have to complete questionnaires at three time points to assess their quality of life (EQ-5D-DL questionnaire) and fear of cancer recurrence (Cancer Worry Scale).",[26,81],"Esophageal Adenocarcinoma",[83,26,84,85,86],"Barrett","Endeavor","Esophageal cancer","Esophageal adenocarcinoma","2026-02-20",{"date":89,"type":35},"2026-02-24",{"date":91,"type":35},"2025-08-13",{"date":93,"type":20},"2027-12",{"name":95,"class":42},"University Hospital, Antwerp",9,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":43},"100281783","pilot-study-for-tce-imaging-of-the-esophagus-using-an-ofdi-capsule-with-a-compact-imaging-system-100281783","NCT02947971","Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System","Pilot Study for TCE (Tethered Capsule Endomicroscopy) Imaging of the Esophagus Using an OFDI (Optical Frequency Domain Imaging) Capsule With a Compact Imaging System","Inclusion Criteria:\n\n* A previous diagnosis of BE (not an inclusion criteria for healthy volunteers)\n* Participants 18 years and older with a previous diagnosis of GERD\n* Participants 14 years and older with a previous diagnosis of EoE (not an inclusion criteria for healthy volunteers)\n* Health participants over the age of 18 but less than 85 years of age\n* Participants must be able to give informed consent\n* Participants must have no solid food for 4 hours prior to the procedure, and only clear liquids for 2 hours prior to the procedure.\n\nExclusion Criteria:\n\n* Participants over 85 years of age\n* Participants with the inability to swallow pills and capsules.\n* Participants with a strong gag reflex\n* Esophageal fistula and\u002For esophageal strictures with a stricture diameter that is smaller than the diameter of the capsule.\n* Participants who are pregnant. In case of women of child bearing age, we will ask them if they are pregnant and if unsure; ask them to take a pregnancy test.",true,"14 Years","85 Years",{"count":108,"type":20},120,[23],"The goal of this research is to test a distal scanning capsule and a compact redesigned version of the OFDI imaging system in healthy and BE participants to assess ease of use, safety and feasibility in preparation for its use in a multicenter clinical trial.",[26],[113,114,115],"Device","OFDI","Tethered Capsule Endomicroscopy","2025-10-20",{"date":118,"type":35},"2025-10-22",{"date":120,"type":35},"2016-04-15",{"date":122,"type":20},"2028-12",{"name":124,"class":42},"Massachusetts General Hospital",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":5},"100079306","genetic-determinants-of-barretts-esophagus-and-esophageal-adenocarcinoma-100079306","NCT00288119","Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma","Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma","FBE","Eligible cases will be defined as those patients and their family members who meet the following criteria:\n\n* Barrett's esophagus confirmed by review of pathology and endoscopy report or adenocarcinoma of the esophagus or family members of person with Barrett's esophagus or adenocarcinoma of the esophagus.\n* Male or female age 18 or older at time of enrollment or male or female less than 18 years of age at time of enrollment with parental consent.\n* Ability to give informed consent, if patient is age 18 or older.",{"count":134,"type":20},2000,"OBSERVATIONAL","The overall objectives of this BETRNet Research Center (RC) are:\n\n1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA)\n2. to increase the biological understanding of key observations made by our clinical researchers;\n3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC;\n4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC;\n5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.",[26,138],"Esophageal Neoplasm",[26],"2025-07-16",{"date":142,"type":35},"2025-07-18",{"date":144,"type":35},"2005-10-01",{"date":146,"type":20},"2028-07-31",{"name":148,"class":42},"Case Western Reserve University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":43},"100224414","australian-barretts-cohort-with-dysplasia-and-early-cancer-study-100224414","NCT02198976","Australian Barrett's Cohort With Dysplasia and Early Cancer Study","ABCDE","Inclusion Criteria:\n\n* Can give informed consent to trial participation\n* Age greater than 18\n* Barrett's oesophagus\n\nExclusion Criteria:\n\n* Age less than 18\n* Pregnant patients","99 Years",{"count":158,"type":20},300,"The purpose of this study is to collect prospective observational data regarding endoscopic management and outcomes of patients with Barrett's oesophagus (BO) with high grade dysplasia and\u002For intramucosal carcinoma. To observe the natural history of patients with low grade dysplastic and non dysplastic Barrett's oesophagus",[26],"2025-03-25",{"date":163,"type":35},"2025-03-27",{"date":165,"type":4},"2014-04",{"date":167,"type":20},"2034-11",{"name":169,"class":42},"Professor Michael Bourke",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100257775","treat-be-study-treatment-with-resection-and-endoscopic-ablation-techniques-for-barretts-esophagus-100257775","NCT02634645","TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)","A Multicenter Prospective Study Evaluating Outcomes of Endoscopic Eradication Therapy in Patients With Barrett's Esophagus Associated Neoplasia: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium","Inclusion Criteria:\n\n* Patients with Barrett's related neoplasia and dysplasia. Patients with esophageal cancer\n\nExclusion Criteria:\n\n* Patients with squamous cell carcinoma","100 Years",{"count":179,"type":20},5000,"A prospective outcomes study in patients with and esophageal cancer (EAC) and Barrett's esophagus (BE) associated neoplasia being evaluated for endoscopic eradication therapy (EET).",[26,182],"Esophageal Cancer","2025-02-25",{"date":185,"type":35},"2025-02-28",{"date":187,"type":4},"2015-01",{"date":189,"type":20},"2027-01",{"name":191,"class":42},"University of Colorado, Denver",4,{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":203,"conditions":204,"keywords":207,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":43},"100101977","barretts-esophagus-related-neoplasia-bern-project-100101977","NCT00590239","Barrett's Esophagus Related Neoplasia (BERN) Project","Endoscopic Detection of Early Neoplasia in Patients With Barrett's Esophagus","BERN","Inclusion Criteria:\n\n* 18-80 years\n* Patients must be able to provide written informed consent\n* Patients referred for endoscopy for screening\u002Fsurveillance of BE or for endoscopic treatment of BE with early mucosal neoplasia\n\nExclusion Criteria:\n\n* Current use of aspirin, non-steroidal anti-inflammatory agents(NSAIDs),or chronic anticoagulants that cannot be discontinued prior to the procedure.\n* Inability to provide written informed consent\n* Significant thrombocytopenia or coagulopathy\n* Any significant co-morbid condition that would prevent the safe administration of conscious sedation",{"count":202,"type":20},150,"* The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia.\n* Endoscopic mucosal resection (EMR) will improve the accuracy for detection of dysplasia\u002Fearly neoplasia.\n\nSpecific Aim 1 - To create a video-atlas of non-dysplastic and dysplastic\u002Fearly neoplastic lesions in patients with BE. This will be used for training purposes and to assess learning curve associated with these new technologies.\n\nSpecific Aim 2 - To create a standardized classification system for the mucosal and vascular patterns observed in patients with BE.\n\nSpecific Aim 3 - To determine the interobserver agreement using the video-atlas for the mucosal and vascular patterns classification agreed upon.\n\nSpecific Aim 4 - To determine the endoscopic detection rate of esophageal cancer or precancerous lesions removed during endoscopy.\n\nSpecific Aim 5 - To determine the pathologic and clinical outcomes of patients undergoing EMR\u002Fablation; including morbidity, mortality and complications of the procedure.\n\nResults to date (June 2008) : this study is active and open to enrollment. Currently 26 patients have enrolled in this study at the Kansas City VA medical center. In order to participate, patients must be eligible for care at the KCVA hospital.",[26,205,206],"Neoplasms","Gastroesophageal Reflux",[26,208,209,210,211],"Neoplasia","Endoscopic mucosal resection","High resolution endoscopy","Chromoendoscopy","2024-11-20",{"date":214,"type":35},"2024-11-22",{"date":216,"type":35},"2007-05-15",{"date":218,"type":20},"2026-12-30",{"name":220,"class":42},"Midwest Biomedical Research Foundation",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":43},"100502116","the-prevalence-risk-factors-and-optimal-biopsy-protocol-of-be-100502116","NCT05818072","The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE","The Prevalence, Risk Factors and Optimal Biopsy Protocol of Barrett's Esophagus in Taiwan - A Prospective Randomized Study","Inclusion Criteria:\n\n* Adults with columnar-lined esophagus\n\nExclusion Criteria:\n\n* A prior history of endoscopic treatment for Barrett's Esophagus\n* A prior history of upper gastrointestinal malignancy\n* A prior history of total or subtotal gastrectomy\n* Esophageal varices noted during the procedure\n* Uncontrolled coagulopathy\n* Taking antiplatelet drug or anticoagulant","20 Years",{"count":230,"type":20},165,[23],"Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.",[26,234],"Intestinal Metaplasia",[26,236,237],"Columnar-lined esophagus","Intestinal metaplasia","2023-05-09",{"date":240,"type":35},"2023-05-11",{"date":242,"type":35},"2023-03-13",{"date":244,"type":20},"2026-12-31",{"name":246,"class":42},"E-DA Hospital",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":104,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":135,"phases":4,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":43},"100100786","progression-of-gastroesophageal-reflux-disease-and-barretts-esophagus-and-the-creation-of-a-barretts-registry-100100786","NCT00574327","Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry","A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.","All patients must be eligible for care that the Kansas City VA Hospital where this study was approved for enrollment.\n\nInclusion Criteria:\n\n* Kansas City VA Patients with confirmed BE with and without dysplasia and patients with reflux disease (patients\u002Fcases); patients with other indicators for endoscopy such as anemia, weight loss, diarrhea, but without GERD and PE (controls).\n\nExclusion Criteria:\n\n* Patients with uncontrolled significant comorbidities such as cardiovascular, pulmonary, renal, hepatic or metabolic diseases.\n* Presence of anticoagulation that would increase risk from biopsies\n* Patients unable to provide history\n* Patients with dyspepsia",{"count":19,"type":20},"The purpose of this study is to determine or evaluate the risk factors such as smoking, family history etc. that cause esophageal cancer and to determine the genetic changes that lead to esophageal cancer. The investigators hypothesis is that systematic collection of data on the natural history of GERD and BE patients and risk factors for development of BE in patients with chronic GERD and progression of BE to dysplasia and adenocarcinoma will provide useful information to develop a decision model for risk stratification and risk reduction strategies in these patients.\n\nAs of March 17, 2011, 585 patients have consented at the Kansas City VA Medical Center.",[26,257,81],"Gastroesophageal Reflux Disease",[259,260,26],"Role","Registry","2023-03-15",{"date":263,"type":35},"2023-03-16",{"date":265,"type":4},"2006-01",{"date":267,"type":20},"2029-01",{"name":220,"class":42}]